The activation of PD-1 on T-cells by its ligands, PD-L1 or PD-L2, are responsible for impairing T-cell activation, proliferation, and cytotoxic secretion, leading to suppression of effective anti-tumor immune responses in cancer. The gene discussed is PDCD1; the disease is neoplasm.